- Lobbying
- Lobbying by Edge Therapeutics, Inc.
Lobbying Relationship
Bills mentioned
H.R.2430: FDA Reauthorization Act of 2017
Sponsor: Greg Walden (R-Ore.)
S.934: FDA Reauthorization Act of 2017
Sponsor: Lamar Alexander (R-Tenn.)
H.R.1648: Ellie's Law
Sponsor: Yvette D. Clarke (D-N.Y.)
S.1999: Ellie's Law
Sponsor: Richard Blumenthal (D-Conn.)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Eugenia Edwards Pierson | House Energy and Commerce Committee (2001-05) |
Pari Mody | Intern, HHS Office of General Counsel Public Health (2013) |
Kristine Blackwood | Dep. Dir. Cong'l Oversight, HHS (2010-15); Chief Counsel, Sen. Aging (2009-10); Investigative Counsel, House Energy & Commerce (2007-08); Attorney-Advisor, USDOJ Ofc of Leg Affairs (2005-07); HC Fraud Coord., USDOJ (2003-05); Asst US Atty (1994-2003) |
Amy Budner Smith | Scheduler, Rep. DeGette (1999-2001) |
Roxana Boyd | Intern, Rep. McIntyre (2012) |
Daniel Kracov | n/a |
Kevin O'Neill | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
U.S. House of Representatives
Food & Drug Administration (FDA)
U.S. House of Representatives
Food & Drug Administration (FDA)
U.S. House of Representatives
Food & Drug Administration (FDA)
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate